Last reviewed · How we verify
Malarone
At a glance
| Generic name | Malarone |
|---|---|
| Also known as | atovaquon/proguanil, atovaquone and proguanil hydrochloride, atovaquone / proguanil hydrochloride, Atovaquone + Proguanil |
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) (PHASE2)
- A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (PHASE1)
- Safety and Efficacy of NF135 CPS Immunization (NA)
- Atoguanil BA Study (PHASE1)
- Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers (PHASE1)
- Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. (PHASE4)
- Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Malarone CI brief — competitive landscape report
- Malarone updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI